Natural Investments LLC Takes Position in Stryker Co. (NYSE:SYK)

Natural Investments LLC purchased a new position in Stryker Co. (NYSE:SYK - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 4,245 shares of the medical technology company's stock, valued at approximately $1,528,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of SYK. Parnassus Investments LLC purchased a new position in shares of Stryker in the third quarter worth about $762,798,000. Raymond James Financial Inc. purchased a new position in Stryker during the fourth quarter worth about $353,394,000. Proficio Capital Partners LLC raised its stake in Stryker by 52,520.8% during the fourth quarter. Proficio Capital Partners LLC now owns 596,194 shares of the medical technology company's stock worth $214,660,000 after purchasing an additional 595,061 shares during the period. RTW Investments LP purchased a new position in Stryker during the third quarter worth about $143,392,000. Finally, State Street Corp raised its stake in Stryker by 2.2% during the third quarter. State Street Corp now owns 14,582,959 shares of the medical technology company's stock worth $5,279,788,000 after purchasing an additional 316,404 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

SYK has been the topic of a number of research analyst reports. JMP Securities reissued a "market perform" rating on shares of Stryker in a research note on Tuesday, February 18th. Argus set a $450.00 price target on shares of Stryker in a research note on Monday, February 3rd. Stifel Nicolaus lifted their price objective on shares of Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a report on Wednesday, January 29th. Royal Bank of Canada lifted their price objective on shares of Stryker from $425.00 to $435.00 and gave the company an "outperform" rating in a report on Wednesday, January 29th. Finally, Truist Financial boosted their price target on shares of Stryker from $409.00 to $413.00 and gave the stock a "hold" rating in a report on Thursday, January 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $421.90.

Remove Ads

Stryker Price Performance

Shares of NYSE SYK opened at $369.16 on Tuesday. The stock has a market cap of $140.87 billion, a price-to-earnings ratio of 47.57, a PEG ratio of 2.93 and a beta of 0.95. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The company's 50-day moving average price is $382.59 and its 200 day moving average price is $373.31. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the company posted $3.46 EPS. As a group, research analysts forecast that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.91%. The ex-dividend date is Monday, March 31st. Stryker's dividend payout ratio (DPR) is 43.30%.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares of the company's stock, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now directly owns 14,895 shares of the company's stock, valued at $5,705,827.65. The trade was a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by corporate insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.